Switch theme
Sign up to access all valuation multiples
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.
1994
28
LTM Revenue $0.1M
LTM EBITDA -$14.8M
$114M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Diamyd Medical has a last 12-month revenue (LTM) of $0.1M and a last 12-month EBITDA of -$14.8M.
In the most recent fiscal year, Diamyd Medical achieved revenue of $13K and an EBITDA of -$14.5M.
Diamyd Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Diamyd Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | XXX | $13K | XXX | XXX | XXX |
| Gross Profit | $0.1M | XXX | -$0.4M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | -2754% | XXX | XXX | XXX |
| EBITDA | -$14.8M | XXX | -$14.5M | XXX | XXX | XXX |
| EBITDA Margin | -14231% | XXX | -108347% | XXX | XXX | XXX |
| EBIT | -$15.6M | XXX | -$15.2M | XXX | XXX | XXX |
| EBIT Margin | -15025% | XXX | -113288% | XXX | XXX | XXX |
| Net Profit | -$15.8M | XXX | -$15.7M | XXX | XXX | XXX |
| Net Margin | -15150% | XXX | -116808% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Diamyd Medical's stock price is SEK 9 (or $1).
Diamyd Medical has current market cap of SEK 1.2B (or $125M), and EV of SEK 1.1B (or $114M).
See Diamyd Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $114M | $125M | XXX | XXX | XXX | XXX | $-0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Diamyd Medical has market cap of $125M and EV of $114M.
Diamyd Medical's trades at 2720.9x EV/Revenue multiple, and -7.8x EV/EBITDA.
Equity research analysts estimate Diamyd Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Diamyd Medical has a P/E ratio of -7.9x.
See valuation multiples for Diamyd Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $125M | XXX | $125M | XXX | XXX | XXX |
| EV (current) | $114M | XXX | $114M | XXX | XXX | XXX |
| EV/Revenue | 1099.3x | XXX | 2720.9x | XXX | XXX | XXX |
| EV/EBITDA | -7.7x | XXX | -7.8x | XXX | XXX | XXX |
| EV/EBIT | -7.3x | XXX | -7.4x | XXX | XXX | XXX |
| EV/Gross Profit | 1099.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.9x | XXX | -7.9x | XXX | XXX | XXX |
| EV/FCF | -7.3x | XXX | -8.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDiamyd Medical's last 12 month revenue growth is 17185%
Diamyd Medical's revenue per employee in the last FY averaged $0K, while opex per employee averaged $0.5M for the same period.
Diamyd Medical's rule of 40 is -12541% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Diamyd Medical's rule of X is 28732% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Diamyd Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17185% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -14231% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -127% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -12541% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 28732% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 74218% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 110534% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Diamyd Medical acquired XXX companies to date.
Last acquisition by Diamyd Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Diamyd Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Diamyd Medical founded? | Diamyd Medical was founded in 1994. |
| Where is Diamyd Medical headquartered? | Diamyd Medical is headquartered in Sweden. |
| How many employees does Diamyd Medical have? | As of today, Diamyd Medical has 28 employees. |
| Who is the CEO of Diamyd Medical? | Diamyd Medical's CEO is Dr. Ulf Hannelius, PhD. |
| Is Diamyd Medical publicy listed? | Yes, Diamyd Medical is a public company listed on STO. |
| What is the stock symbol of Diamyd Medical? | Diamyd Medical trades under DMYD B ticker. |
| When did Diamyd Medical go public? | Diamyd Medical went public in 2013. |
| Who are competitors of Diamyd Medical? | Similar companies to Diamyd Medical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Diamyd Medical? | Diamyd Medical's current market cap is $125M |
| What is the current revenue of Diamyd Medical? | Diamyd Medical's last 12 months revenue is $0.1M. |
| What is the current revenue growth of Diamyd Medical? | Diamyd Medical revenue growth (NTM/LTM) is 17185%. |
| What is the current EV/Revenue multiple of Diamyd Medical? | Current revenue multiple of Diamyd Medical is 1099.3x. |
| Is Diamyd Medical profitable? | Yes, Diamyd Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Diamyd Medical? | Diamyd Medical's last 12 months EBITDA is -$14.8M. |
| What is Diamyd Medical's EBITDA margin? | Diamyd Medical's last 12 months EBITDA margin is -14231%. |
| What is the current EV/EBITDA multiple of Diamyd Medical? | Current EBITDA multiple of Diamyd Medical is -7.7x. |
| What is the current FCF of Diamyd Medical? | Diamyd Medical's last 12 months FCF is -$15.7M. |
| What is Diamyd Medical's FCF margin? | Diamyd Medical's last 12 months FCF margin is -15076%. |
| What is the current EV/FCF multiple of Diamyd Medical? | Current FCF multiple of Diamyd Medical is -7.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
